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BACKGROUND. Cancer incidence rates vary among American Indian and Alaska
Native (AI/AN) populations and often differ from rates among non-Hispanic
whites (NHWs). However, the misclassification of race for AI/AN cancer cases in
central cancer registries may have led to underestimates of the AI/AN cancer
burden in previous reports.
METHODS. Cases diagnosed during 1999 through 2004 were identified from popu-
lation-based cancer registries in the United States. Age-adjusted rates were calcu-
lated for the 25 most common sites for AI/ANs and NHWs. To minimize the
misclassification of race, cancer registry records were linked with patient registra-
tion files from the Indian Health Service (IHS). Analyses were restricted to Contract
Health Service Delivery Area (CHSDA) counties and were stratified by IHS region.
RESULTS. In CHSDA counties, cancer incidence rates among AI/ANs varied
widely by region, whereas rates among NHWs did not. For all cancer sites com-
bined, AI/AN rates were higher than NHW rates among both males and females
in the Northern and Southern Plains, and among Alaska Native Females; AI/AN
rates were lower than NHW rates in the Southwest, the Pacific Coast, and the
East. Lung cancer and colorectal cancer rates for AI/ANs exceeded rates for
NHWs in Alaska and the Northern Plains. Rates for stomach, gallbladder, kidney,
and liver cancer were higher among AI/ANs than among NHWs overall, in Alaska,
in the Plains regions, and in the Southwest.
CONCLUSIONS. Regional differences in cancer incidence rates among AI/AN
populations were not obvious from nationwide data and highlighted opportu-
nities for cancer control and prevention. It is unlikely that such differences
are explained by race misclassification. Cancer 2008;113(5 suppl):1142–52.
Published 2008 by the American Cancer Society.*
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T here is wide variation in cancer incidence andmortality rates worldwide.1-3 Historically, system-
atic examination of differences in cancer occurrence
by geographic region and among different cultures
has yielded important clues about etiology.4 Such dif-
ferences may also point to opportunities for cancer
prevention and control.
Cancer incidence rates for American Indian and
Alaska Native (AI/AN) populations vary by geo-
graphic region in the United States and often differ
from those of non-Hispanic whites (NHWs).5-7 How-
ever, the misclassification of AI/AN cancer cases as
other races in central cancer registries often has dis-
torted the true burden of disease in these popula-
tions.8-12 Systematic linkage of records from central
cancer registries with patient registration records
from the Indian Health Service (IHS) has been sug-
gested to address this problem.13
The articles assembled in this Cancer supple-
ment provide a comprehensive overview of the bur-
den of cancer among AI/AN populations in the
United States at the beginning of the 21st century.
The objective of this report is to present incidence
rates for the most common types of cancer among
AI/ANs, by region and sex, in a format that enables
the reader to assess the relative contribution of each
type of cancer to the overall burden of the disease
both within and between geographic regions.
Region-specific rates for NHW populations are pre-
sented for comparison.
MATERIALS AND METHODS
Data Sources
Incident cancer cases that were diagnosed during the
period from 1999 through 2004 were identified from
population-based registries that participate in the
National Cancer Institute’s Surveillance, Epidemiol-
ogy, and End Results (SEER) Program14 and/or the
Centers for Disease Control and Prevention’s National
Program of Cancer Registries (NPCR).15 For this
study, participating registries classified tumor histol-
ogy, tumor behavior, and primary cancer site accord-
ing to the 3rd edition of the International
Classification of Diseases for Oncology (ICD-O).16
Detailed descriptions of the data sources and meth-
ods used for this analysis are provided in another ar-
ticle in this supplement.17
Incidence rates are presented for all cancer sites
combined and for the most common 25 cancer sites
among AI/AN populations nationwide; site categories
are consistent with prevailing reporting standards.15
Lymphomas (ICD-O histology codes 9590-9729) are
presented as 2 separate categories (ie, Hodgkin and
non-Hodgkin lymphoma) and are not included with
other tumors of specific anatomic sites. Mesothe-
lioma (ICD-O histology codes 9050-9055) and Kaposi
sarcoma (ICD-O histology code 9140) are not
included with other tumors of specific anatomic
sites. In situ and invasive bladder tumors are com-
bined in a single category.18 All other benign and in
situ tumors (ICD-O behavior codes 0 and 2, respec-
tively) are excluded from the analysis, as are tumors
of uncertain or unknown behavior (ICD-O behavior
code 1).
To identify AI/AN cancer cases that were mis-
classified as other races, states worked with the IHS
to link cancer registry records with IHS patient regis-
tration files. AI/AN individuals must provide proof of
membership in a federally recognized tribe to receive
healthcare from the IHS. The provision of healthcare
to AI/AN populations by the IHS is greatest in Con-
tract Health Service Delivery Area (CHSDA) counties,
which generally are defined as counties that contain
or are adjacent to federally recognized tribal reserva-
tions and/or trust lands.19 There also is evidence that
misclassification of AI/AN race occurs less often in
CHSDA counties.20 For this reason, 1 set of incidence
rates was calculated for residents of all United States
counties, and a second set of rates was calculated for
residents of CHSDA counties.
Incidence rates also were calculated for each of 6
IHS regions (Alaska, Pacific Coast, Northern Plains,
Southern Plains, Southwest, and East) and for all
regions combined (Fig. 1). These IHS regions were
chosen because they are consistent with previous
reports of regional patterns of specific health out-
comes and disease risk factors for AI/ANs.21-23 Rank
order of cancer sites by IHS region was based on the
value of the respective site-specific incidence rates.
Statistical Analyses
Incidence rates were expressed per 100,000 popula-
tion and were age-adjusted by the direct method24
using the 2000 United States standard population.25
The annual percentage change (APC) was used to
describe fixed interval trends from 1999 to 2004. Inci-
dence rates, rate ratios, APC, and 95% confidence
limits were calculated with version 6.3 of SEER*Stat
software.26 Denominators for rate calculations were
derived from population estimates from the U.S. Bu-
reau of the Census.27 Incidence counts were sup-
pressed when fewer than 6 cases were observed to
protect confidentiality. The APC was suppressed if it
was based on fewer than 10 cases for at least 1 year
within the time interval.
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RESULTS
Incidence rates for AI/AN populations residing in
CHSDA counties were higher than rates for AI/AN
residents in all counties combined (Table 1). In con-
trast, NHW rates did not differ appreciably between
CHSDA counties and all counties. These findings are
consistent with improved classification of AI/AN can-
cer cases within CHSDA counties; therefore, the
remaining portion of this report will focus on rates
calculated for residents of CHSDA counties.
In CHSDA counties, incidence rates for all cancer
sites combined among AI/AN males ranged from
256.2 in the Southwest to 636.1 in the Northern
Plains (Table 2). Rates for NHW males ranged from
505.0 in the Southwest to 574.4 in the East. Among
AI/AN males, the top 5 incident cancers were pros-
tate, lung and bronchus (lung), colon and rectum
(colorectal), kidney and renal pelvis (kidney), and uri-
nary bladder (bladder) for all regions except Alaska
and the Southwest, although the rankings varied. In
Alaska and the Southwest, stomach replaced bladder
cancer in the top 5 cancer sites (Table 2). AI/AN pros-
tate cancer rates were highest in the Northern and
Southern Plains and were similar to rates for NHW
males. Lung and colorectal cancer rates among AI/AN
males were highest in the Northern Plains and Alaska,
and were significantly higher than those for NHW
males. In the Southern Plains, AI/AN males also had
high rates of lung cancer that were similar to the rates
for NHW males, and colorectal cancer rates among
AI/AN males in this region were significantly higher
than for NHW males. AI/AN males in the Southwest
had the lowest rates for the top 3 sites. AI/AN rates
for cancers of the kidney, stomach, and liver/intrahe-
patic bile ducts (liver) generally were higher than
those in NHW males in most regions. Gallbladder
cancer rates for AI/AN males were nearly 4-fold
greater than for NHW males for all regions combined
and were more than 6 times greater in the Southwest
and Alaska.
Among AI/AN females in CHSDA counties, inci-
dence rates for all sites combined ranged from 218.3
in the Southwest to 500.7 in Alaska (Table 3). Rates
for NHW females ranged from 398.9 in the Southwest
to 437.9 in both the Pacific Coast and the East. Breast
was the most common site among AI/AN females
and NHW females in all regions. Breast, colorectal,
and uterine cancer were among the top 5 cancers
among AI/AN females in all regions. Lung cancer
was among the top 5 in all regions except the South-
west. Non-Hodgkin lymphoma was in the top 5
among AI/AN females in the Plains and Pacific
Coast; kidney cancer was in the top 5 among AI/AN
females in Alaska, the East, and the Southwest; and
ovarian cancer was in the top 5 among AI/AN
females in the Southwest. Breast cancer was signifi-
FIGURE 1. States and Contract Health Service Delivery Area (CHSDA) counties by Indian Health Service region are illustrated.
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TABLE 1
Incidence Rates and Annual Percentage Change, Both Sexes Combined, Contract Health Service Delivery Area Counties
and All Counties: United States, 1999-2004
AI/ANa NHW AI/AN:NHWa
Type of Cancer Rateb Count APCc Rateb Count APCc RR 95% CI
CHSDA Counties
All sites 368.4 22,165 21.14 475.9 1,311,488 21.32c 0.77d 0.76–0.78
Prostate 105.6 2475 21.93 154.4 194,792 22.62 0.68d 0.66–0.71
Breast 85.3 3041 21.83 134.4 195,290 23.03c 0.63d 0.61–0.66
Lung and bronchus 57.4 3165 20.22 70.3 197,074 21.18c 0.82d 0.79–0.85
Colon and rectum 46.3 2621 23.02 50.8 143,160 23.03c 0.91d 0.87–0.95
Corpus and uterus, NOS 18.1 650 0.37 23.6 34,780 21.21 0.77d 0.71–0.83
Kidney and renal pelvis 18.2 1152 3.31 12.6 34,648 3.09c 1.45d 1.36–1.54
NHL 14.1 845 20.13 19.4 53,309 20.06 0.73d 0.67–0.78
Ovary 11.5 405 25.32 14.4 21,224 23.02c 0.80d 0.72–0.88
Urinary bladder 9.6 518 22.11 23.9 67,366 20.72c 0.40d 0.37–0.44
Pancreas 9.9 540 20.06 10.8 30,562 0.00 0.91d 0.83–1.00
Stomach 10.8 606 21.49 5.8 16,258 21.70c 1.88d 1.72–2.05
Cervix uteri 9.4 381 26.82c 7.4 9374 24.50c 1.28d 1.15–1.42
Leukemia 9.4 673 20.70 12.6 34,025 22.07c 0.75d 0.69–0.81
Liver and intrahepatic bile duct 9.0 529 4.04 4.3 11,805 2.64c 2.11d 1.92–2.32
Oral cavity and pharynx 8.5 548 21.62 11.0 30,245 20.74c 0.77d 0.70–0.84
Myeloma 6.2 355 22.51 4.9 13,656 20.29 1.27d 1.14–1.42
Thyroid 5.6 452 5.24 8.3 20,567 7.15c 0.67d 0.61–0.74
Melanoma of the skin 4.8 314 1.45 21.7 57,228 2.04 0.22d 0.20–0.25
Esophagus 4.4 248 23.65 5.1 14,166 0.12 0.87d 0.76–0.99
Brain 3.6 299 24.77 6.9 17,897 20.02 0.53d 0.46–0.59
Testis 4.1 204 22.95 6.7 7643 20.04 0.61d 0.53–0.70
Larynx 3.1 189 26.11 3.8 10,522 24.12c 0.81d 0.69–0.94
Gallbladder 3.3 170 20.55 0.9 2618 22.69c 3.59d 3.04–4.22
Soft tissue including heart 2.1 157 22.60 2.9 7707 0.83 0.70d 0.59–0.84
Other biliary 2.2 114 4.12 1.5 4177 4.82c 1.48d 1.21–1.80
All Counties
All sites 275.5 28,874 21.92 479.0 6,010,914 21.21c 0.58d 0.57–0.58
Prostate 83.5 3429 23.21 153.4 865,550 23.27c 0.54d 0.52–0.56
Breast 65.5 4090 22.34 131.7 879,456 22.78c 0.50d 0.48–0.51
Lung and bronchus 43.8 4166 20.89 72.4 921,867 20.64c 0.61d 0.59–0.62
Colon and rectum 33.9 3316 24.04c 53.2 681,745 22.72c 0.64d 0.61–0.66
Corpus and uterus, NOS 13.3 829 1.31 24.6 166,098 21.25c 0.54d 0.50–0.58
Kidney and renal pelvis 12.6 1393 3.07 13.4 167,890 3.29c 0.94d 0.89–0.99
NHL 10.5 1100 20.27 19.7 246,109 20.04 0.53d 0.50–0.57
Ovary 8.3 505 25.10 14.3 96,461 22.82c 0.58d 0.53–0.64
Urinary bladder 7.6 693 24.18 23.7 304,365 20.43c 0.32d 0.29–0.34
Pancreas 7.3 691 20.25 10.9 140,444 0.26 0.67d 0.62–0.73
Stomach 7.2 701 22.55 6.1 77,735 22.18c 1.19d 1.10–1.29
Cervix uteri 6.9 502 26.89c 7.7 45,935 24.15c 0.90d 0.82–0.99
Leukemia 6.8 846 22.10 12.7 156,354 21.48 0.54d 0.50–0.58
Liver and intrahepatic bile duct 6.5 681 2.83 4.3 54,317 2.03c 1.52d 1.40–1.64
Oral cavity and pharynx 6.4 718 21.22 10.9 135,624 20.25 0.59d 0.54–0.63
Myeloma 4.6 451 25.00 4.9 63,283 20.83 0.93 0.84–1.02
Thyroid 4.0 595 6.92 8.5 98,144 6.67c 0.47d 0.43–0.52
Melanoma of the skin 3.6 424 0.08 19.6 236,723 2.67c 0.18d 0.16–0.20
Esophagus 3.2 309 25.61 5.0 63,176 0.66c 0.63d 0.56–0.71
Brain 2.9 406 27.13c 6.9 81,271 20.61 0.42d 0.38–0.47
Testis 2.8 260 21.86 6.5 34,389 0.39 0.43d 0.38–0.49
Larynx 2.3 246 28.56 4.2 52,828 22.74c 0.54d 0.47–0.61
Gallbladder 2.1 189 20.72 1.0 13,123 22.54c 2.11d 1.80–2.44
(continued)
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cantly lower among AI/AN females than among
NHW females in all regions except Alaska, where the
rates were similar. Lung and colorectal cancer rates
for AI/AN females were highest in Alaska and the
Plains regions and exceeded the rates for NHW
females in those areas. Lung cancer rates for AI/AN
females were lowest in the Southwest (20% of the
rate for NHW females). Cervical cancer was signifi-
cantly higher among AI/AN than among NHW
females in the Plains. Cancers of the kidney, stom-
ach, liver, and gallbladder generally were higher
among AI/AN females than among NHW females
with some regional variation. Incidence rate tables
combining data from males and females for the top
25 cancers and for all cancers collectively, by IHS
region, are available at http://www.cdc.gov/cancer/
healthdisparities/what_cdc_is_doing/aiansupplement.
htm accessed on July 15, 2008.
DISCUSSION
Results from this report are consistent with previous
accounts of AI/AN cancer incidence6,7 and mortal-
ity.21,23,28 Regional differences in cancer incidence
rates may reflect geographic variation in population
screening and/or in risk factors, including tobacco
abuse, obesity, physical inactivity, heavy alcohol con-
sumption, dietary factors, and prevalence of infec-
tious agents that are believed to cause cancer. In
some instances, there is compelling evidence to link
such risk factors with observed cancer rates. For
example, high rates of lung cancer in Alaska and in
the Northern and Southern Plains regions generally
are consistent with high rates of tobacco abuse in
these areas.7,29 For other cancers, additional research
is needed to 1) elucidate risk factors and determi-
nants for the regional variations, and 2) develop new
approaches for implementing culturally appropriate
cancer prevention and control strategies. Risk factors
for specific cancers are addressed in detail in other
articles included in this supplement.
AI/AN populations generally have a lower preva-
lence of screening for colorectal, breast, and cervical
cancer, which can affect stage at diagnosis, clinical
outcomes, and, in some cases, incidence, as reported
by Steele et al29 in this supplement and previously. It
has been demonstrated that cervical cancer screen-
ing programs, coupled with adequate diagnostic fol-
low-up and treatment, clearly benefit AI/AN
populations.30 The success of such screening pro-
grams underscores the potential for expanding other
recommended cancer screening modalities in these
communities. Cancer control only recently has
become an important concern for many AI/AN com-
munities, because cancer surveillance has revealed
substantial increases in cancers that once were rare
in this population.31-34 Several governmental, public,
and private organizations are collaborating to foster
the establishment of comprehensive cancer control
programs within tribes and other communities.35
This study also has identified several cancers for
which AI/AN incidence rates consistently exceeded
the rates in NHW populations. The incidence of kid-
ney cancer was nearly 50% greater for AI/AN popula-
tions than for NHW populations in all regions
combined and was elevated in 4 of 6 regions exam-
TABLE 1
(continued)
AI/ANa NHW AI/AN:NHWa
Type of Cancer Rateb Count APCc Rateb Count APCc RR 95% CI
Soft tissue including heart 1.6 207 21.84 3.0 35,240 0.97c 0.53d 0.45–0.62
Other biliary 1.5 137 2.73 1.5 19,031 4.49c 1.04 0.87–1.24
Source: Cancer registries in Centers for Disease Control and Prevention’s National Program of Cancer Registries (NPCR) and/or the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER)
Program.
CHSDA indicates Contract Health Service Delivery Area; AI/AN, American Indians/Alaska Natives; NHW, non-Hispanic whites; APC, annual percentage change; RR, rate ratio; CI, confidence interval; NOS, not
otherwise specified; NHL, non-Hodgkin lymphoma.
aAI/AN race is reported by NPCR and SEER registries or through linkage with the IHS patient registration database. AI/AN persons of Hispanic origin are included.
bRates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups).
c The APC is statistically significant (P < .05).
d The RR is statistically significant (P < .05). Counts <6 are suppressed; if no were cases reported, then rates and RRs could not be calculated.
Years of data and registries used: 1999-2004 (41 states and the District of Columbia): Alaska,* Alabama,* Arkansas, Arizona,* California,* Colorado,* Connecticut,* the District of Columbia, Delaware, Florida,*
Georgia, Hawaii, Iowa,* Idaho,* Illinois, Indiana,* Kentucky, Louisiana,* Massachusetts,* Maine,* Michigan,* Minnesota,* Missouri, Montana,* North Carolina,* Nebraska,* New Hampshire, New Jersey, New Mex-
ico,* Nevada,* New York,* Ohio, Oklahoma,* Oregon,* Pennsylvania,* Rhode Island,* Texas,* Utah,* Washington,* Wisconsin,* West Virginia, and Wyoming*; 1999 and 2002-2004: North Dakota*; 2001-2004: South
Dakota*; 2003-2004: Mississippi* and Virginia; 2004: Tennessee (asterisks indicate states with at least 1 county designated as a CHSDA).
Percentage regional coverage of AI/AN in CHSDA counties to AI/AN in all counties: Alaska, 100%; East, 13.1%; Northern Plains, 59.0%; Southern Plains, 64.1%; Pacific Coast, 55.6%; Southwest, 87.5%.
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TABLE 2
Incidence Rates, Ranks, and Rate Ratios of the Top 25 Cancers for American Indian/Alaska Native Males Compared With Non-Hispanic White
Males by Indian Health Service Region in Contract Health Service Delivery Area Counties: United States, 1999-2004
All Regions Combined Northern Plains Alaska
AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW
Type of Cancer Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR
All sites/types — 414.6 — 549.2 0.75b — 636.1 — 541.8 1.17b — 538.7 — 569.8 0.95
Prostate 1 105.6 1 154.4 0.68b 1 174.6 1 162.2 1.08 3 78.3 1 180.7 0.43b
Lung and bronchus 2 69.6 2 85.9 0.81b 2 119.8 2 84.6 1.42b 1 115.3 2 85.0 1.36b
Colon and rectum 3 52.6 3 59.8 0.88b 3 88.9 3 61.3 1.45b 2 98.5 3 61.4 1.60b
Kidney/renal pelvis 4 23.2 7 17.2 1.35b 4 29.2 7 17.2 1.70b 5 28.6 6 18.7 1.53b
Urinary bladder 5 16.5 4 41.5 0.40b 5 26.8 4 39.4 0.68b 6 23.0 4 47.3 0.49b
NHL 6 15.2 6 23.1 0.65b 7 19.2 5 22.8 0.84 11 13.2 5 26.3 0.50b
Stomach 7 14.7 12 8.5 1.74b 8 18.7 12 8.5 2.21b 4 34.6 14 7.8 4.46b
Oral cavity/pharynx 8 13.1 8 16.4 0.80b 6 22.6 9 15.5 1.45b 8 20.5 8 15.4 1.33
Liver/IHBD 9 12.7 16 6.4 2.00b 10 16.0 17 5.4 2.98b 9 17.2 12 8.2 2.09b
Leukemia 10 11.5 9 16.3 0.71b 9 17.6 8 16.3 1.08 12 8.4 9 15.2 0.55b
Pancreas 11 9.8 10 12.5 0.78b 13 9.0 10 11.6 0.78 7 21.4 10 9.6 2.22b
Esophagus 12 8.1 11 8.7 0.93 11 15.2 11 9.3 1.64b 10 13.3 11 9.3 1.43
Myeloma 13 6.7 17 6.3 1.06 14 8.9 14 6.6 1.35 19 2.7 16 6.1 0.44
Melanoma, skin 14 5.8 5 26.6 0.22b 18 3.5 6 18.8 0.18b 25 1.6 7 16.4 0.10b
Larynx 15 5.5 15 6.6 0.84b 12 9.3 16 6.5 1.43 15 5.4 17 5.2 1.04
Brain 16 4.5 13 8.3 0.54b 16 4.7 13 8.0 0.58b 17 3.3 13 7.8 0.42b
Testis 17 4.1 14 6.7 0.61b 15 5.1 14 6.6 0.77 14 6.2 15 7.1 0.86
Gallbladder 18 2.5 33 0.7 3.69b 20 2.7 33 0.7 3.97b 16 4.6 33 0.6 7.38b
Thyroid 19 2.4 18 4.4 0.55b 17 4.6 18 3.9 1.17 21 2.4 18 5.1 0.47
Other biliary 20 2.4 24 1.9 1.26 27 1.2 23 1.8 0.64 13 6.5 25 1.4 4.81b
Soft tissue including heart 21 2.1 19 3.5 0.59b 23 2.0 20 3.2 0.63 28 0.9 20 3.9 0.24b
Hodgkin lymphoma 22 1.7 20 3.3 0.51b 19 2.9 19 3.3 0.8 30 0.9 21 3.6 0.24
Penis 23 1.3 31 0.8 1.69b 21 2.4 29 0.8 2.90b 26 1.1 31 0.8 1.53
Bones and joints 24 1.1 27 1.1 1.00 28 1.0 26 1.1 0.89 24 2.1 27 0.9 2.34
Anorectum 25 1.1 26 1.3 0.84 24 1.8 28 0.9 2.09 18 3.0 26 1.2 2.56
Southern Plains Pacific Coast East
AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW
Type of Cancer Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR
All sites/types — 573.4 — 547.5 1.05b — 338.0 — 557.8 0.61b — 308.9 — 574.4 0.54b
Prostate 1 156.7 1 146.5 1.07 1 83.2 1 160.8 0.52b 1 83.9 1 155.9 0.54b
Lung and bronchus 2 111.0 2 108.5 1.02 2 57.7 2 82.5 0.70b 2 51.0 2 91.5 0.56b
Colon and rectum 3 70.3 3 63.2 1.11 3 44.0 3 56.5 0.78b 3 31.1 3 65.8 0.47b
Kidney/renal pelvis 4 25.1 8 17.8 1.41b 4 15.2 8 16.8 0.90 5 15.3 7 18.7 0.82
Urinary bladder 5 25.0 4 35.0 0.71b 5 14.1 4 42.0 0.34b 4 22.8 4 44.8 0.51b
NHL 6 24.2 5 22.1 1.10 7 12.5 6 24.2 0.52b 13 5.5 6 24.0 0.23b
Stomach 12 10.5 14 7.2 1.46b 8 12.2 13 8.3 1.48b 10 7.9 11 10.1 0.79
Oral cavity/pharynx 7 18.4 7 18.3 1.00 9 12.2 7 17.1 0.71b 6 11.3 9 16.3 0.69
Liver/IHBD 11 11.1 15 6.1 1.81b 6 12.8 15 6.6 1.95b 12 7.3 15 6.8 1.06
Leukemia 8 17.6 9 16.3 1.08 10 9.7 9 16.7 0.58b 7 9.0 8 17.1 0.53b
Pancreas 9 12.1 10 13.0 0.94 12 6.8 10 12.8 0.53b 11 7.9 10 13.4 0.59
Esophagus 14 8.4 13 7.7 1.09 11 7.4 12 8.8 0.84 8 8.9 12 8.9 1.00
Myeloma 15 8.3 16 5.8 1.43b 14 5.0 16 6.5 0.77 15 3.8 16 6.6 0.57
Melanoma, skin 10 11.9 6 20.3 0.58b 13 6.3 5 32.0 0.20b 16 3.4 5 25.8 0.13b
Larynx 13 9.0 12 7.7 1.16 16 3.8 17 5.8 0.65b 9 8.0 14 7.8 1.02
Brain 16 7.6 11 8.4 0.90 17 3.4 11 8.8 0.38b 14 4.7 13 8.1 0.57
Testis 17 3.4 17 5.6 0.62b 15 3.8 14 7.2 0.53b 20 1.5 17 6.5 0.23b
(continued)
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ined.36 Stomach and liver cancer incidence rates
were higher among AI/ANs than among NHWs in
most regions.37,38 Finally, gallbladder incidence rates
were 4 times greater among AI/AN populations than
among NHW populations in all regions combined
and in 4 of 6 IHS regions.39 Possible contributors to
the regional patterns in AI/AN populations for these
cancers are explored in separate articles of this sup-
plement.36-39
Similar methods and findings were described
recently in the 2007 Annual Report to the Nation on
the Status of Cancer7 (ARN); however, the current
TABLE 2
(continued)
Southern Plains Pacific Coast East
AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW
Type of Cancer Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR
Gallbladder 23 1.5 33 0.7 2.29 25 0.8 35 0.6 1.43 21 1.3 33 0.8 1.64
Thyroid 24 1.5 19 3.1 0.48b 18 2.3 18 4.1 0.56b 19 1.7 18 4.9 0.35
Other biliary 20 2.9 22 1.7 1.65 19 2.3 24 1.9 1.18 25 0.9 23 2.0 0.45
Soft tissue including heart 18 3.3 20 2.9 1.14 20 2.2 19 3.8 0.58b 26 0.8 19 3.6 0.22b
Hodgkin lymphoma 19 3.1 18 3.3 0.93 21 1.4 20 3.3 0.41b 23 1.2 20 3.5 0.34
Penis 27 1.4 29 1.0 1.42 26 0.8 34 0.7 1.12 32 0.0 31 0.8 —
Bones and joints 26 1.4 26 1.2 1.24 28 0.7 27 1.1 0.58 18 2.0 27 1.1 1.83
Anorectum 25 1.5 28 1.1 1.32 23 0.8 25 1.6 0.53 32 0.0 26 1.3 —
Southwest
AI/AN NHW AI/AN:NHW
Type of Cancer Rank Ratea Rank Ratea RR
All sites/types 0 256.2 0 505.0 0.51b
Prostate 1 65.7 1 133.8 0.49b
Lung and bronchus 4 21.2 2 77.3 0.27b
Colon and rectum 2 25.7 3 55.1 0.47b
Kidney/renal pelvis 3 25.2 7 15.7 1.60b
Urinary bladder 11 5.7 4 40.7 0.14b
NHL 7 10.9 6 20.4 0.54b
Stomach 5 15.3 13 7.1 2.17b
Oral cavity/pharynx 12 4.7 8 15.3 0.30b
Liver/IHBD 6 12.3 15 6.3 1.95b
Leukemia 9 7.0 9 14.2 0.49b
Pancreas 8 7.9 10 11.4 0.69b
Esophagus 13 4.6 11 8.0 0.58b
Myeloma 9 7.0 17 5.3 1.32
Melanoma, skin 17 3.3 5 28.6 0.11b
Larynx 19 2.1 16 5.9 0.35b
Brain 16 3.3 12 7.6 0.44b
Testis 14 4.3 14 6.3 0.68b
Gallbladder 15 4.1 32 0.7 6.21b
Thyroid 18 2.5 18 5.2 0.48b
Other biliary 20 2.0 23 1.8 1.12
Soft tissue including heart 21 1.7 19 3.5 0.48b
Hodgkin lymphoma 26 0.8 20 2.8 0.27b
Penis 23 1.3 33 0.6 2.10
Bones and joints 24 0.9 27 1.0 0.84
Anorectum 28 0.5 26 1.2 0.43
Source: Cancer registries in the Centers for Disease Control and Prevention’s National Program of Cancer Registries and/or the National Cancer Institute’s Surveillance, Epidemiology and End Results Program
(for the states included, see Table 1).
AI/AN indicates American Indians/Alaska Natives; NHW, non-Hispanic whites; RR, rate ratio; NHL, non-Hodgkin lymphoma; IHBD, intrahepatic bile ducts.
a Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups).
b The RR is statistically significant (P < .05).
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TABLE 3
Incidence Rates, Ranks, and Rate Ratios of the Top 25 Cancers for American Indian/Alaska Native Females Compared With Non-Hispanic White
Females, by Indian Health Service Region, CHSDA Counties: United States, 1999-2004
All Regions Combined Northern Plains Alaska
AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW
Type of Cancer Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR
All sites/types 0 337.6 0 424.0 0.80b 0 471.1 0 410.7 1.15b 0 500.7 0 417.2 1.20b
Breast 1 85.3 1 134.4 0.63b 1 115.9 1 130.3 0.89b 1 134.9 1 136.5 0.99
Lung and bronchus 2 48.5 2 58.6 0.83b 2 93.8 2 51.1 1.83b 3 75.4 2 60.7 1.24b
Colon and rectum 3 41.6 3 43.6 0.95 3 59.8 3 45.1 1.33b 2 106.2 3 40.6 2.62b
Corpus/uterus, NOS 4 18.1 4 23.6 0.77b 4 19.5 4 26.6 0.74b 5 13.6 4 22.8 0.60b
Kidney/renal pelvis 5 14.2 12 8.7 1.62b 5 19.3 11 9.2 2.10b 8 12.0 11 8.6 1.39
NHL 6 13.1 6 16.4 0.80b 6 18.0 5 16.6 1.08 10 9.9 5 17.9 0.55b
Ovary 7 11.5 7 14.4 0.80b 9 11.0 6 14.0 0.79 13 7.3 6 13.5 0.54b
Pancreas 8 9.8 11 9.4 1.04 8 12.5 12 8.9 1.40b 9 11.9 10 10.7 1.12
Cervix uteri 9 9.4 13 7.4 1.28b 7 12.5 13 7.4 1.69b 11 8.5 13 6.2 1.37
Thyroid 10 8.5 8 12.1 0.70b 10 9.7 8 11.8 0.83 6 12.3 8 12.4 0.99
Stomach 11 7.9 17 3.6 2.18b 12 9.2 17 3.4 2.69b 4 17.7 18 3.0 5.90b
Leukemia 12 7.6 10 9.7 0.78b 11 9.6 10 9.9 0.97 18 5.7 9 10.9 0.52b
Liver/IHBD 13 5.8 20 2.5 2.36b 14 6.5 21 2.2 2.89b 15 6.9 19 2.7 2.51b
Myeloma 14 5.8 16 3.7 1.56b 16 5.9 16 4.0 1.49 12 7.5 16 4.0 1.88
Oral cavity/pharynx 15 4.8 14 6.3 0.75b 13 7.6 14 6.2 1.23 7 12.3 15 5.8 2.12b
Urinary bladder 16 4.5 9 10.5 0.43b 15 6.4 9 10.4 0.62b 16 6.4 12 8.6 0.74
Melanoma, skin 17 4.0 5 18.0 0.22b 17 5.3 7 13.8 0.38b 29 1.11 7 12.7 0.08b
Gallbladder 18 3.9 28 1.1 3.50b 22 2.5 26 1.3 1.89 14 6.9 32 0.9 7.91b
Brain 19 3.0 15 5.7 0.52b 20 2.8 15 5.4 0.53b 22 2.6 14 6.0 0.43b
Other biliary 20 2.1 27 1.2 1.77b 29 1.01 27 1.2 0.83 19 3.6 24 1.5 2.42
Soft tissue including heart 21 2.0 19 2.5 0.82 18 3.4 20 2.4 1.42 23 2.4 21 2.4 0.99
Vulva 22 1.6 21 2.4 0.67b 21 2.8 19 2.4 1.17 28 1.11 17 3.4 0.32
Esophagus 23 1.6 22 2.1 0.76 19 3.1 22 2.0 1.55 17 6.2 23 2.1 2.98b
Larynx 24 1.2 24 1.5 0.80 24 2.1 23 1.5 1.39 24 1.71 26 1.3 1.39
Anorectum 25 1.2 23 1.8 0.68b 27 1.8 25 1.3 1.38 20 3.0 20 2.5 1.21
Southern Plains Pacific Coast East
AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW
Type of Cancer Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR
All sites/types 0 440.9 0 402.1 1.10b 0 295.1 0 437.9 0.67b 0 272.0 0 437.9 0.62b
Breast 1 115.7 1 129.7 0.89b 1 74.7 1 142.6 0.52b 1 71.4 1 133.6 0.53b
Lung and bronchus 2 69.9 2 62.6 1.12b 2 48.0 2 60.9 0.79b 2 43.5 2 61.7 0.71b
Colon and rectum 3 53.8 3 43.2 1.25b 3 35.0 3 42.1 0.83b 3 39.7 3 47.1 0.84
Corpus/uterus, NOS 4 22.4 4 19.4 1.16 4 16.7 4 23.6 0.71b 4 15.2 4 25.4 0.60b
Kidney/renal pelvis 6 18.1 10 9.1 1.99b 7 10.2 12 8.3 1.23 5 14.0 12 9.2 1.53
NHL 5 18.5 5 15.6 1.18 5 12.5 6 16.8 0.74b 6 8.8 5 16.9 0.52b
Ovary 7 14.7 6 14.0 1.05 8 10.0 7 14.9 0.67b 11 5.9 7 14.8 0.40b
Pancreas 9 10.1 11 8.7 1.16 6 11.1 10 9.7 1.15 9 7.0 10 10.2 0.69
Cervix uteri 8 14.1 9 9.2 1.54b 10 6.9 13 7.0 0.98 8 7.1 13 7.3 0.97
Thyroid 11 9.2 13 8.1 1.13 11 6.3 8 11.0 0.57b 10 6.6 8 13.6 0.49b
Stomach 13 7.6 17 3.4 2.23b 13 4.7 17 3.5 1.34 13 4.8 16 4.4 1.09
Leukemia 10 9.6 8 9.7 1.00 9 7.5 11 9.7 0.77 7 7.5 11 9.8 0.77
Liver/IHBD 17 5.1 18 2.8 1.84b 12 5.8 20 2.6 2.24b 15 3.8 21 2.5 1.55
Myeloma 15 6.6 16 3.7 1.79b 15 4.1 16 3.8 1.08 12 4.9 17 3.9 1.25
Oral cavity/pharynx 16 6.0 14 6.0 1.00 17 3.8 14 6.7 0.57b 16 3.7 14 6.5 0.58
Urinary bladder 14 7.3 12 8.5 0.85 14 4.3 9 10.1 0.42b 14 4.4 9 12.0 0.37b
Melanoma, skin 12 7.8 7 12.4 0.63b 16 4.0 5 22.6 0.18b 19 1.91 6 16.7 0.12b
(continued
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report differs from the ARN in several respects. First,
this report includes rates for 25 of the most common
cancer sites, whereas the ARN was restricted to 15
sites. Second, the ARN suppressed publication of
rates based on fewer than 16 cases, whereas the cur-
rent report applied a less restrictive suppression rule
to present rates for more cancer sites among AI/AN
populations. Finally, for this supplement, the investi-
gators analyzed data from additional states with
significant AI/AN populations (Minnesota, North
Carolina, and South Dakota) that were not included
in the ARN analysis.
TABLE 3
(continued)
Southern Plains Pacific Coast East
AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW AI/AN NHW AI/AN:NHW
Type of Cancer Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR Rank Ratea Rank Ratea RR
Gallbladder 20 2.6 27 1.0 2.65b 19 2.0 29 1.1 1.80 21 1.81 27 1.1 1.61
Brain 18 4.8 15 5.7 0.84 18 3.1 15 5.9 0.52b 18 2.4 15 5.8 0.42b
Other biliary 24 1.6 26 1.1 1.49 23 1.1 28 1.1 0.98 31 0.41 26 1.3 0.31
Soft tissue including heart 19 2.8 21 2.1 1.36 27 0.8 19 2.6 0.32b 27 0.71 20 2.6 0.26
Vulva 23 1.8 19 2.6 0.69 20 1.8 22 2.2 0.81 17 2.61 19 2.7 0.97
Esophagus 27 1.5 24 1.5 0.96 22 1.1 21 2.2 0.51 24 1.11 22 2.2 0.48
Larynx 22 2.0 23 1.8 1.10 21 1.4 27 1.3 1.11 25 0.91 23 1.8 0.49
Anorectum 21 2.1 22 1.8 1.14 25 0.9 23 2.1 0.41b 26 0.81 24 1.6 0.48
Southwest
AI/AN NHW AI/
AN:NHW
Type of Cancer Rank Ratea Rank Ratea RR
All sites/types 0 218.3 0 398.9 0.55b
Breast 1 50.8 1 125.2 0.41b
Lung and bronchus 6 10.4 2 56.3 0.18b
Colon and rectum 2 17.3 3 39.7 0.44b
Corpus/uterus, NOS 3 16.7 4 19.6 0.86b
Kidney/renal pelvis 5 12.4 12 8.2 1.51b
NHL 8 8.8 7 14.7 0.60b
Ovary 4 12.5 8 13.6 0.92
Pancreas 11 7.7 11 8.4 0.92
Cervix uteri 10 7.8 13 7.3 1.07
Thyroid 7 8.9 6 14.8 0.60b
Stomach 9 8.6 17 3.0 2.86b
Leukemia 15 5.8 10 9.1 0.63b
Liver/IHBD 13 6.3 19 2.3 2.71b
Myeloma 14 6.2 16 3.1 2.04b
Oral cavity/pharynx 17 2.1 14 5.9 0.37b
Urinary bladder 21 1.4 9 10.1 0.14b
Melanoma, skin 19 1.8 5 17.8 0.10b
Gallbladder 12 6.6 29 0.9 7.20b
Brain 20 1.8 15 5.6 0.32b
Other biliary 16 3.6 27 1.0 3.64b
Soft tissue including heart 18 2.0 18 2.5 0.83
Vulva 23 0.8 21 2.2 0.37b
Esophagus 26 0.61 23 1.7 0.35b
Larynx 39 0.21 24 1.4 0.11b
Source: Cancer registries in the Centers for Disease Control and Prevention’s National Program of Cancer Registries and/or the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program
(for the states included, see Table 1).
AI/AN indicates American Indians/Alaska Natives; NHW, non-Hispanic whites; RR, rate ratio; NOS, not otherwise specified; NHL, non-Hodgkin lymphoma; IHBD, intrahepatic bile ducts.
a Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups).
b The RR is statistically significant (P < .05).
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Results from this report must be interpreted in
the context of the following limitations. The record-
linkage methodology used to reduce AI/AN misclas-
sification relied on records of individuals who
received healthcare from the IHS; this method does
not address misclassification among AI/ANs who
were not listed in IHS files. Furthermore, the current
analysis was restricted to residents of CHSDA coun-
ties, where it is believed that this methodology is
most efficacious. The cancer burden among AI/ANs
who do not receive healthcare from the IHS and
among AI/AN residents of non-CHSDA counties has
not been well characterized. For this reason, the
direction or extent of possible bias that may have
been introduced by the current methodology is not
known.
Despite limitations of the data, this and other
reports in the supplement offer the most compre-
hensive examination to date of cancer incidence in
AI/AN populations. The inclusion of data from most
central cancer registries in the United States
strengthens the stability of regional estimates of AI/
AN cancer incidence, whereas data linkages and the
focus on CHSDA counties improves on the race clas-
sification and, thus, on the accuracy of the estimates.
In conclusion, the quality and scope of cancer
surveillance in AI/AN populations has been strength-
ened. Our report and the other reports in this sup-
plement describe disparities in cancer incidence, risk
factors, and screening prevalence that provide a
clear, albeit challenging, course of action for cancer
control partners. Future progress in decreasing the
cancer burden in AI/AN populations is necessary
and achievable with the implementation of compre-
hensive cancer control programs. Ideally, these pro-
grams would provide direction and would motivate
and actively engage partners across the spectrum of
cancer control advocates, healthcare providers, pol-
icymakers, tribal leaders, and funding agencies.
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